Instrument Inactif

Communiqués Reunion Neuroscience

Actions

FTRP

CA76134G1037

Produits pharmaceutiques

Communiqués

01/08/23	Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement	AQ
17/07/23	REUNION NEUROSCIENCE OBTAINS FINAL COURT ORDER FOR PROPOSED PLAN OF ARRANGEMENT	AQ
14/07/23	Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement	AQ
13/07/23	Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement	AQ
07/07/23	Reunion Neuroscience : Annual Information Form For the Fiscal Year Ended March 31, 2023 - Form 6-K	PU
29/06/23	Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	AQ
20/06/23	Reunion Neuroscience : NOTICE OF SPECIAL MEETING OF SHAREHOLDERS - Form 6-K	PU
06/06/23	Traders Insights: Stocks Making Moves After Announcing News: REUN, WLDS, SPRC, QBTS	AQ
01/06/23	Reunion Neuroscience : Announces US$13.1 Million Take-Private Transaction with MPM BioImpact - Form 6-K	PU
01/06/23	Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact	AQ
25/04/23	Reunion Neuroscience : Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency - Form 6-K	PU
25/04/23	Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference	AQ
25/04/23	Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency	AQ
03/04/23	Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors	AQ
27/03/23	Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting	AQ
14/03/23	Reunion Neuroscience : Files Lawsuit Against Mindset Pharma - Form 6-K	PU
13/03/23	Reunion Neuroscience Files Lawsuit Against Mindset Pharma	AQ
07/03/23	Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference	AQ
14/02/23	Reunion Neuroscience : (FORMERLY FIELD TRIP HEALTH LTD.) UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K	PU
14/02/23	Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results	AQ
03/02/23	REUNION NEUROSCIENCE SCHEDULES FISCAL THIRD QUARTER 2023 CONFERENCE CALL FOR TUESDAY FEBRUARY 14, 2023, AT 8:30 A.M. ET	AQ
02/02/23	Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET	AQ
18/01/23	Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer	AQ
09/01/23	Reunion Neuroscience : Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104 - Form 6-K	PU
09/01/23	Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104	AQ